Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The current trial shall clarify the potential of the multitarget antiangiogenic tyrosinkinase
inhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage
treatment in patients with recurrent, pretreated ovarian cancer.